and gene therapy.
Dogs were probably the first animals to be domesticated by man, and have certainly had a close association with human settlements since palaeolithic times. They have been bred for particular anatomical or behavioural traits for many thousands of years so that already by between 4000 and 5000 years ago many distinct types were kept by the civilisations of Egypt and subsequently Babylon and Assyria. During this long association with man, and especially in the last 150 years in which formal breed standards have been recognised, the breeding of dogs in genetically isolated pools has allowed the emergence of a large number (>400) of inherited diseases. The meeting had the twin objectives of familiarising human geneticists with the wealth of resources presented by the many inherited diseases described in the dog, and familiarising those working-in canine disease with the most recent developments in the analysis of human genetic diseases.
In keeping with these themes, the meeting began with a session surveying the genetics of connective tissue and skeletal abnormalities. In the mouse the full panoply of transgenic methodologies and in the human the power of modem positional closing have been brought to bear. In the dog, in which the diversity of skeletal phenotypes considered normal by breed societies is probably greater than in any other species, little if any molecular work has yet been done. Malcolm Willis (Newcastle) reported on hip dysplasia (HD) which is the most common skeletal abnormality recognised by veterinarians. The heritability for this trait when measured by radiological assessment is 40%, but this is probably still too low for conventional genetic mapping to isolate the genes responsible. Matthew Warman (Case Western Reserve University, Cleveland) then spoke about the insights that studies of osteochondrodysplasias in mouse and humans can provide into skeletal morphogenesis. The role of the burgeoning family ofcollagen genes received special attention as Dr Warman described the differences in effect of col 1 Oa 1 mutation in man and mouse (col 1 Oa 1 null causes spondylometaphyseal dysplasia in man, but in mouse is phenotypically silent). Dr Warman described mutations in two further collagens which give rise to skeletal and joint abnormalities in both species. Part of this is the contribution of a small number of high penetrance loci (for instance, in the breast these loci account for about 5% of all cancers) but a substantial proportion is attributable to mutations at much lower penetrance loci. Molecular studies of canine tumourigenesis are in their infancy, as Gerard Rutteman (Utrecht) made clear. George Padgett (Michigan State University), who has studied histiocytosis and mast cell tumours in the Bernese Mountain Dog, provided an example of how breed specific predispositions to a particular tumour may shed light on the same tumour in humans, but also of the difficulties involved in studying the genetics of a partially penetrative trait without performing a deliberate outcross. Olyvind Bruland (Oslo) reported his studies of clinical and therapeutic aspects of osteosarcoma. In humans this is a rare tumour, so the availability of giant canine breeds, in which the same tumour is common, has contributed greatly to his studies of monoclonal antibody based therapy.
The second day opened with a discussion of the comparative genetics of sensory deficiencies in mouse, dog, and man, an area where monogenic disorders predominate, and where developments in the dog have sometimes led those in human medicine. Karen Steel (MRC, Nottingham) divided inherited deafness in the mouse into morphogenetic defects of the inner ear, linked syndromically with other skeletal defects, cochleosaccular defects often associated with abnormalities of pigmentation, and neuroepitheleal defects where morphogenesis is normal but subsequently degeneration and dysfunction occur. For all three forms some of the responsible genes have been isolated (for morphogenetic defects, pax-3 in the splotch mouse; for cochleosaccular defects (as well as pax-3), c-kit, mgf, mi, and trp-1, and most recently she and Steve Brown (St Mary's, London) The final day was devoted to muscular dystrophies and gene therapy, two sessions that provide a complementary perspective on genetic disease and therapeutic strategies since muscular dystrophies have been an ongoing target in the development of gene therapy approaches. Terry Partridge (Hammersmith Hospital, London) began by discussing the mdx mouse mutant and its use as a model for human Duchenne muscular dystrophy and the study of pathological processes involved in muscle degeneration. He focused on extensive studies of the fates of myogenic cells grafted into mdx muscles. Several important considerations of this approach for therapeutic purposes include the age of the donor in relation to the proliferative potential of transplanted myogenic cells as well as the viability of this approach in larger mammals, for example, dog or human where therapeutic potential may be compromised by the ability of transplanted cells to disperse. Nick Sharp (University of North Carolina) subsequently introduced the canine and feline models of DMD, including Golden Retriever muscular dystrophy (GRMD) emphasising some of the pathological similarities and differences. The advantages of studying the same or similar mutations in different mammalian species were emphasised throughout the discussion. GRMD results from a splice site mutation that leads to skipping of the seventh exon of the dystrophin gene and predicted premature termination. Surprisingly, GRMD dogs show very low levels of a near normal sized dystrophin protein. Even small increases in dystrophin expression can have a beneficial effect and GRMD dogs may represent an interesting system to assess routes to ameliorate the condition by increasing production of the near normal dystrophin. Eric Hoffman (Pittsburgh) discussed the American Quarter horse, a breed that carries a mutation for hyperkalaemic periodic paralysis. Hyperkalaemic periodic paralysis occurs in the human population and has been shown to be the result of mutations in the skeletal muscle voltage sensitive sodium channel gene. A phenylalanine to valine mutation in the homologous horse gene is responsible for periodic paralysis in American Quarter horses and accurate molecular diagnosis is now available to the horse breeding community. Linda Cork introduced a large pedigree of dogs inheriting the autosomal dominant hereditary canine spinal muscular atrophy (HCSMA) locus. A variety of approaches, including the use of microsatellites and gene markers, is being used to identify a genetic map linkage for HCSMA. Keith Johnson (Charing Cross and Westminster Medical School, London) concluded the session with a detailed summary of work to date on the molecular basis for the myotonic dystrophy (DM) gene. There are no known animal models of DM and indeed the basis of the DM mutation, a triplet repeat expansion, has not been shown to underlie a genetic disease in any other species. Dominic Wells (Royal Veterinary College, London) continued the morning's theme by discussing his experiments on muscle gene therapy also using the mdx mouse. He described three approaches towards the introduction of constructs: (1) the use of retroviral vectors; (2) adenoviral vectors; and (3) injection of naked plasmid. The most successful system in the mouse was plasmid DNA injection, retroviral approaches being compounded by immuno-logical problems with the endogenous proviruses present in some strains of mice. Adenoviral systems were also compromised by immunological problems as mouse muscle matures. However, direct DNA injection is confounded by problems of scale and it is clearly important that plasmid be introduced when the target tissue is still growing or following regeneration. There are few results yet on similar approaches in the GRMD dog. John Wolfe (University of Pennsylvania) focused on gene therapy for lysosomal storage disease using the dog model for mucopolysaccharidosis type VII. The strategy used is cross correction; the normal lysosomal enzyme can be synthesised by one cell and exported to enzyme negative mutant cells. Its full exploitation will depend both on the production of outcrosses to simplify genetic studies and on the development of the canine genetic map. Both of these topics were major themes of the Second Dogmap conference in Cambridge, which immediately followed the Wellcome Trust meeting.
